



Healthcare Development & Innovation Group

Healthcare News and Deals - December 16th, 2025

1. Tebra secures \$250M from Hildred and J.P. Morgan to accelerate AI automation for private healthcare practices

The financing will fund Tebra's AI initiatives to automate documentation, billing, payments, and marketing for private healthcare practices. Through its EHR+ platform, the company aims to reduce administrative workloads using tools like AI Note Assist and automated revenue systems, expanding efficiency and innovation for over 140,000 provider users. ([Link](#))

2. OpenAI-backed Chai Discovery raises \$130M Series B led by General Catalyst and Oak HC/FT, with participation from Menlo Ventures, OpenAI, Dimension, Thrive Capital, Yosemite venture fund, SV Angel and Emerson Collective to advance AI-driven molecular design at \$1.3B valuation

The funding will accelerate Chai Discovery's AI-driven molecular and drug design platform, expanding its computer-aided suite for faster therapeutic development. Its Chai 2 model shows higher success in designing de novo antibodies. Combining deep learning and biochemistry, the company targets complex diseases unmet by traditional discovery methods. ([Link](#))

3. Atavistik Bio raises \$120M Series B led by Nextech Invest and The Column Group to advance precision allosteric therapies for HHT and MPNs

The investment will propel Atavistik Bio's development of allosteric small molecules for HHT and MPNs using its AMPST[™] discovery platform. Funding supports AKT1- and JAK2-selective inhibitors built to minimize toxicity and enable long-term treatment. The HHT program is slated to begin clinical testing in early 2026. ([Link](#))

4. Addition Therapeutics emerges from stealth with \$100M funding led by SR One, Pivotal Life Sciences, and the Gates Foundation to advance PRINT genetic medicine platform

The company introduced its all-RNA, nonviral PRINT platform for precise, one-time genomic insertion therapies using lipid nanoparticles. Backed by major investors, it aims to develop safer, scalable treatments for chronic and rare diseases. Early efforts include a program for lifelong HIV antibody protection, with preclinical studies starting next year. ([Link](#))

5. Link Cell Therapies launches with \$60M Series A led by Johnson & Johnson Innovation, with participation from Samsara BioCapital and Sheatree Capital and Bristol Myers Squibb to advance logic-gated CAR-T treatments for solid and liquid tumors

The company is developing next-generation CAR-T therapies that activate only when multiple tumor-specific antigens are present, improving safety and precision for solid and liquid tumors. Its lead candidate, LNK001 for renal cell carcinoma, enters Phase 1 trials next year, with a colorectal cancer program to follow in 2027. ([Link](#))

6. Aeovian Pharmaceuticals raises \$55M Series B co-led by Luma Group and CTI Life Sciences Fund with participation from Foresite Capital, Symbiosis, Apollo Health Ventures, Hevolution, Sofinnova Investments, and venBio to advance selective mTORC1 inhibitor AV078 for TSC-related epilepsy

The funding will advance Aeovian's AV078, a selective mTORC1 inhibitor designed to treat refractory epilepsy linked to tuberous sclerosis complex. The therapy aims to improve brain penetration, safety, and seizure control over existing treatments, supporting completion of a Phase 2 proof-of-concept study targeting TSC-related neurodevelopmental and metabolic dysfunctions. ([Link](#))

7. Valerie Health raises \$30M Series A led by Redpoint Ventures, with participation from BoxGroup, General Catalyst, Primary Venture Partners, Karman Ventures, .406 Ventures and Waybury Capital to scale AI-driven front-office automation for independent provider groups

The funding will enhance Valerie Health's AI platform for automating front-office tasks like referrals, faxes, and scheduling within medical practices. Using human-supervised AI, it structures data and improves efficiency, cutting costs and boosting revenue. The company plans to expand into voice workflows, analytics, and strengthen operations amid rising demand. ([Link](#))

8. Codoxo raises \$35M Series C led by CVS Health Ventures, with participation from Wipro Ventures, 450 Ventures, Sands Capital, 111 West Capital, Brewer Lane Ventures, QED Investors and Echo Health Ventures to advance generative AI platform for proactive payment integrity in healthcare

The funding will enhance Codoxo's generative AI platform for proactive payment integrity, detecting errors and fraud before claims are paid. Its Point Zero model integrates AI across pre- and post-payment stages to reduce waste, disputes, and costs while supporting education, compliance, and expanding adoption among U.S. health plans. ([Link](#))

9. Wearinq raises \$14M Series A led by AIX Ventures with participation from SpringTide, Berkeley Catalyst Fund, Lightscape Partners, Alumni Ventures, Amino Capital, LDV Partners, Maliam, XB Ventures, Device of Tomorrow Capital, NYX Ventures Partners and SmartLink Partners, to scale eWave wireless heart monitor

The funding will support nationwide rollout of Wearinq's eWave, a wireless 6-lead ECG monitor providing continuous heart data and real-time clinician reports. Operating over five days per charge, it detects arrhythmias and will expand to other cardiac conditions, advancing accessible remote monitoring to reduce early heart disease deaths. ([Link](#))

10. Auxira Health raises \$7.8M seed round led by Route 66 Ventures and Abundant Venture Partners to expand virtual cardiology platform

The funding will help Auxira Health expand its virtual cardiology platform by growing partnerships, technology infrastructure, and clinical staff. Its hybrid model supports cardiologists through remote teams handling routine care and documentation, reducing wait times and improving efficiency. The company aims to serve 100 specialists by mid-2026. ([Link](#))

11. Trethera receives \$2.7M NIH grant to study TRE-515 in combination with KRAS inhibitors for treatment-resistant non-small cell lung cancer

The grant supports studies of Trethera's TRE-515 combined with KRAS inhibitors to overcome resistance in non-small cell lung cancer. By targeting the dCK enzyme essential for cancer cell survival, the therapy aims to enhance response rates and prevent relapse, extending Trethera's strategy against treatment-resistant tumors. ([Link](#))

12. Attivare Therapeutics receives \$6.6M Gates Foundation grant to develop long-lasting malaria vaccine using ATTimune bioscaffold platform

The grant supports Attivare's development of a malaria vaccine using its ATTimune bioscaffold platform for long-lasting immunity. Based on Wyss Institute technology, it delivers antigens and adjuvants via slow-release silica rods to sustain immune response. The project aims to create affordable, durable vaccines suited for low-resource, malaria-endemic regions. ([Link](#))

13. NeuroWorx closes oversubscribed seed round led by Nexus NeuroTech Ventures, with participation from Foothill Ventures, Verge HealthTech Fund and Wisconsin Alumni Research Foundation to advance bioelectronic therapy for CNS disorders

The funding will advance NeuroWorx's Cerebrovascular Pacing System™, a bioelectronic therapy targeting brain vascular and fluid clearance dysfunctions tied to neurodegenerative and psychiatric diseases. Building on University of Wisconsin-Madison research, proceeds will support team growth, clinical translation, and regulatory progress using biomarker-driven approaches to improve brain health outcomes. ([Link](#))

Events:

1. January 12th - 15th - JPM Healthcare Conference

The 44th Annual J.P. Morgan Healthcare Conference will be held from January 12-15, 2026, at the Westin St. Francis Hotel in San Francisco, CA. The conference is a major industry event that brings together healthcare leaders, investors, and innovators, and it features a range of events and networking opportunities throughout the week. ([Link](#))

2. January 22nd - Policy and Practice Forum - How to Build Healthy and Resilient Communities Through Human-Centered AI

HDIG is producing this interactive workshop, along with Onix, and HDIG Sr. Research Fellows from UNC and Wake Forest University, will fill gaps in awareness and access for practitioners in industry, research and governance. This event is hosted by Innovate Carolina and Chapel Hill Mayor, Jessica Anderson. ([Link](#))

HDIG

Healthcare Development & Innovation Group



HDIG SEARCH



HDIG PARTNERS



HDIG FUNDS